IP Library Granted Patent US 9,839,653
Granted Patent B2
US 9,839,653 · App. 15/029,206 · Granted Dec 12, 2017

Method for reducing the inflammatory activity of a stem cell transplant and use thereof

Inventors: Johannes Petrus Jozef Maria De Munter (Banholt, NL); Ekkehard Lang (Weinbach, DE); Erik Charles Marie Joseph Wolters (Amsterdam, NL); Petrus Theodorus De Haan (Oegstgeest, NL)
Assignee: NEUROPLAST BEHEER B.V.
A61K35/28A01K67/0271A61K35/16A61K38/1722C12N5/0087C12N5/0647C12N5/0663A01K2207/30A01K2227/105A01K2267/0356A01K2267/0368A61K2035/124C12N2533/56
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,839,653
App. No.
15/029,206
Granted
Dec 12, 2017
Kind
B2
Abstract

The disclosure is in the field of cell therapy, more in particular, stem cell transplantation therapy. The disclosure provides methods and compositions for improving the efficacy of stem cell transplantation therapy by reducing the inflammatory activity of a stem cell transplant. More in particular, the disclosure provides a method for preparing a stem cell transplant with reduced inflammatory activity comprising a step of suspending a composition comprising stem cells in a fibrinogen-depleted plasma and/or in a fibrinogen and C-reactive protein-depleted plasma.

Claims (9)

1. An in vitro method for producing a hematopoietic stem cell composition with reduced inflammatory activity, the method comprising:

suspending a composition comprising nucleated cells comprising at least one stem cell in plasma or serum depleted of fibrinogen and C-reactive protein,

thereby obtaining a stem cell composition with reduced inflammatory activity.

2. The method according to claim 1 , wherein the composition comprising nucleated cells is obtained from a tissue sample taken from a subject.

3. The method according to claim 2 , wherein the subject is a human subject.

4. The method according to claim 2 , wherein the plasma or serum depleted of fibrinogen and C-reactive protein is obtained from the same subject as the subject from which the tissue sample is obtained.

5. The method according to claim 1 , additionally comprising a step of depleting pro-inflammatory cells from the composition comprising nucleated cells.

6. The method according to claim 1 , wherein the fibrinogen and C-reactive protein depleted plasma or serum is obtained by filtration and/or chromatography.

7. The method according to claim 2 , wherein the tissue is selected from the group consisting of hone marrow, peripheral blood and umbilical cord blood.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 14, 2017
From: DE MUNTER, JOHANNES PETRUS JOZEF MARIA; LANG, EKKEHARD; WOLTERS, ERIK CHARLES MARIE JOSEPH; DE HAAN, PETRUS THEODORUS
To: NEUROPLAST BEHEER B.V.
Reel/Frame 043282/0672 →
Priority Claims (1)
EP 13190120 · Oct 24, 2013 · regional
Continuity (1)
Related Publication 20160228468A1 · Aug 11, 2016